Publications
Genome engineering: the next genomic revolution." Nature Methods 11, no. 10 (2014): 1009-1011.
"Genome Engineering of Stem Cells for Autonomously Regulated, Closed-Loop Delivery of Biologic Drugs." Stem Cell Reports 8, no. 5 (2017): 1202-1213.
"Genome Engineering for Personalized Arthritis Therapeutics." Trends in Molecular Medicine 23, no. 10 (2017): 917-931.
"Genome engineering: a new approach to gene therapy for neuromuscular disorders." Nature Reviews. Neurology 13, no. 11 (2017): 647-661.
"Genome editing: the end of the beginning." Genome Biology 16 (2015).
"Genetic Engineering of Mesenchymal Stem Cells for Differential Matrix Deposition on 3D Woven Scaffolds." Tissue Engineering. Part A 24, no. 19-20 (2018): 1531-1544.
"Genetic engineering for skeletal regenerative medicine." Annual Review of Biomedical Engineering 9 (2007): 87-119.
"Genetic engineering: Chemical control for CRISPR editing." Nature Chemical Biology 13, no. 1 (2017): 2-3.
"Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma." Nature Communications 8 (2017).
"Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy." Human Genetics 135, no. 9 (2016): 1029-1040.
"Gene therapies for hemophilia hit the mark in clinical trials." Nature Medicine 24, no. 2 (2018): 121-122.
"Gene targeting to the ROSA26 locus directed by engineered zinc finger nucleases." Nucleic Acids Research 40, no. 8 (2012): 3741-3752.
"Gene targeting to the ROSA26 locus directed by engineered zinc finger nucleases." Nucleic Acids Research 40, no. 8 (2012): 3741-3752.
"Gene Delivery into Cells and Tissues." (2013): 687-723.
"Gene delivery and biomedical engineering." Current Opinion in Biomedical Engineering 7 (2018): iii - v.
"Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy." Molecular Therapy : the Journal of the American Society of Gene Therapy 29, no. 11 (2021): 3243-3257.
"From CRISPR scissors to virus sensors." Nature 557, no. 7704 (2018): 168-169.
"Expanding the CRISPR Toolbox: Targeting RNA with Cas13b." Molecular Cell 65, no. 4 (2017): 582-584.
"Erratum: Reading Frame correction by targeted genome editing restores dystrophin expression in cells from duchenne muscular dystrophy patients (Molecular Therapy (2013) 21 (1718-1726) DOI: 10.1038/mt.2013.111)." Molecular Therapy 21, no. 11 (2013): 2130.
"Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers." Nat Biotechnol 33, no. 5 (2015): 510-517.
"An enhancer-based gene-therapy strategy for spatiotemporal control of cargoes during tissue repair." Cell Stem Cell 30, no. 1 (2023): 96-111.e6.
"Enhancer RNAs predict enhancer-gene regulatory links and are critical for enhancer function in neuronal systems." Nucleic Acids Research 48, no. 17 (2020): 9550-9570.
"Enhancer Histone Acetylation Modulates Transcriptional Bursting Dynamics of Neuronal Activity-Inducible Genes." Cell Reports 26, no. 5 (2019): 1174-1188.e5.
"Enhanced MyoD-induced transdifferentiation to a myogenic lineage by fusion to a potent transactivation domain." Acs Synthetic Biology 4, no. 6 (2015): 689-699.
"Engineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression." Methods (San Diego, Calif.) 69, no. 2 (2014): 188-197.
"